CD8A and neoplasm: In preclinical models of PC, ibrutinib combined with gemcitabine increased the levels of effector CD8+ T cells and mast cell inhibition, decreased angiogenesis, and reduced desmoplasia in multiple mouse models, resulting in reduced tumor size and increased survival rate (10, 23).